Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.25259/IJDVL_799_2024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Apremilast in Chronic Graft-Versus-Host Disease: A Paediatric Case Report.
Clin Exp Dermatol
November 2024
Department of Dermatology, La Paz University Hospital, Madrid, Spain.
Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis.
J Dermatol
December 2024
Department of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Article Synopsis
- Deucravacitinib, an oral tyrosine kinase 2 inhibitor, is approved globally for treating adults with moderate to severe plaque psoriasis, especially those needing systemic therapy.
- A systematic review and meta-analysis analyzed its efficacy in Asian populations compared to other treatments, revealing significant improvement over placebo and apremilast.
- In Asian patients, deucravacitinib showed PASI 75 and 90 response rates that are comparable to several biologics, highlighting its effectiveness and convenience as an oral treatment option.
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial.
Ann Rheum Dis
October 2024
Providence St. Joseph Health, Swedish Medical Center, Seattle, Washington, USA.
Objectives: Oligoarticular psoriatic arthritis (PsA) is frequent but rarely studied. The objective was to assess the efficacy of apremilast in early oligoarticular PsA.
Methods: FOREMOST (NCT03747939) was a phase 4 multicentre, randomised, double-blind, placebo-controlled trial.
Apremilast versus betamethasone oral mini-pulse in the treatment of progressive non-segmental vitiligo: A randomised pilot trial.
Indian J Dermatol Venereol Leprol
July 2024
Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
Dermatol Ther (Heidelb)
August 2024
Alliance Clinical Trials and Probity Medical Research, Waterloo, ON, Canada.
Introduction: Deucravacitinib, a novel, oral, selective allosteric tyrosine kinase 2 inhibitor, demonstrated superiority versus placebo and apremilast in the POETYK PSO-1 and PSO-2 studies. We describe patient-reported outcomes with deucravacitinib treatment versus placebo and apremilast in these studies.
Methods: Two multicenter, global, double-blind, placebo- and active comparator-controlled studies randomized patients with moderate-to-severe plaque psoriasis 1:2:1 to placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!